RESULTS OF A PILOT CLINICAL TRIAL OF DENDRITICCELL BASED VACCINES FOR TREATMENT OF RECURRENT HERPESVIRUS INFECTION

Chronic recurrent infections caused by herpes simplex virus (HSV) types 1 and 2 represent a serious medical and social challenge. Given an important role of immune system in surveillance of viral infections, an induced enhancement of antigen-specific immune response seems to be a promising approach...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	O. Yu. Leplina, N. M. Starostina, D. D. Blinova, O. I. Zheltova, E. A. Oleinik, T. V. Tyrinova, A. A. Ostanin, E. R. Chernykh
Formato:	article
Lenguaje:	RU
Publicado:	SPb RAACI 2016
Materias:	pilot study herpesvirus infection dendritic cells therapeutic vaccines Immunologic diseases. Allergy RC581-607
Acceso en línea:	https://doaj.org/article/d12c8a468ba3469c88b1c2fa7c457f10
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:d12c8a468ba3469c88b1c2fa7c457f10
record_format	dspace
spelling	oai:doaj.org-article:d12c8a468ba3469c88b1c2fa7c457f102021-11-18T08:03:45ZRESULTS OF A PILOT CLINICAL TRIAL OF DENDRITICCELL BASED VACCINES FOR TREATMENT OF RECURRENT HERPESVIRUS INFECTION1563-06252313-741X10.15789/1563-0625-2016-5-425-436https://doaj.org/article/d12c8a468ba3469c88b1c2fa7c457f102016-08-01T00:00:00Zhttps://www.mimmun.ru/mimmun/article/view/1066https://doaj.org/toc/1563-0625https://doaj.org/toc/2313-741XChronic recurrent infections caused by herpes simplex virus (HSV) types 1 and 2 represent a serious medical and social challenge. Given an important role of immune system in surveillance of viral infections, an induced enhancement of antigen-specific immune response seems to be a promising approach to treatment of recurrent HSV infections, in particular, using dendritic cell (DCs) vaccines. The present paper contains results of an open pilot study evaluating efficacy and safety of dendritic-cell vaccines in the patients with recurrent HSV infections. Twenty-nine patients including 14 persons with labial herpes, and 15, with genital herpes have been enrolled in this study. DCs were generated in presence of GM-CSF and IFNα and then loaded with recombinant viral proteins (HSV1gD or HSV2gD). These cells were applied in 2 rounds of vaccination performed within 9 months. Immunotherapy with DCs did not induce sufficient side effects, and was accompanied by more than two-fold decrease in relapse rate and increased length of remissions during the 9-month period of treatment. Later on, we revealed a reduced frequency of relapses, and a 3-fold increase in remission duration over the subsequent 6-month follow up. The clinical effect during the treatment and at later terms (a half-year observation) was noted with both labial and genital herpes, as registered in the majority of patients, being associated with induction of antigen-specific proliferative response and normalization of reduced mitogenic responsiveness of mononuclear cells towards ConA. The patients’ survey at longer terms (more than 24 months) has shown that the beneficial effect of immunotherapy, in terms of reduced relapse rates, was maintained in 77.8% of the respondents by 48 months (a median follow-up term). At this time, the antigen specific proliferative response was maintained in 66.7% of patients. The data obtained suggest that the dendritic-cell vaccines may be a promising approach to the treatment of recurrent labial and genital herpes.O. Yu. LeplinaN. M. StarostinaD. D. BlinovaO. I. ZheltovaE. A. OleinikT. V. TyrinovaA. A. OstaninE. R. ChernykhSPb RAACIarticlepilot studyherpesvirus infectiondendritic cellstherapeutic vaccinesImmunologic diseases. AllergyRC581-607RUMedicinskaâ Immunologiâ, Vol 18, Iss 5, Pp 425-436 (2016)
institution	DOAJ
collection	DOAJ
language	RU
topic	pilot study herpesvirus infection dendritic cells therapeutic vaccines Immunologic diseases. Allergy RC581-607
spellingShingle	pilot study herpesvirus infection dendritic cells therapeutic vaccines Immunologic diseases. Allergy RC581-607 O. Yu. Leplina N. M. Starostina D. D. Blinova O. I. Zheltova E. A. Oleinik T. V. Tyrinova A. A. Ostanin E. R. Chernykh RESULTS OF A PILOT CLINICAL TRIAL OF DENDRITICCELL BASED VACCINES FOR TREATMENT OF RECURRENT HERPESVIRUS INFECTION
description	Chronic recurrent infections caused by herpes simplex virus (HSV) types 1 and 2 represent a serious medical and social challenge. Given an important role of immune system in surveillance of viral infections, an induced enhancement of antigen-specific immune response seems to be a promising approach to treatment of recurrent HSV infections, in particular, using dendritic cell (DCs) vaccines. The present paper contains results of an open pilot study evaluating efficacy and safety of dendritic-cell vaccines in the patients with recurrent HSV infections. Twenty-nine patients including 14 persons with labial herpes, and 15, with genital herpes have been enrolled in this study. DCs were generated in presence of GM-CSF and IFNα and then loaded with recombinant viral proteins (HSV1gD or HSV2gD). These cells were applied in 2 rounds of vaccination performed within 9 months. Immunotherapy with DCs did not induce sufficient side effects, and was accompanied by more than two-fold decrease in relapse rate and increased length of remissions during the 9-month period of treatment. Later on, we revealed a reduced frequency of relapses, and a 3-fold increase in remission duration over the subsequent 6-month follow up. The clinical effect during the treatment and at later terms (a half-year observation) was noted with both labial and genital herpes, as registered in the majority of patients, being associated with induction of antigen-specific proliferative response and normalization of reduced mitogenic responsiveness of mononuclear cells towards ConA. The patients’ survey at longer terms (more than 24 months) has shown that the beneficial effect of immunotherapy, in terms of reduced relapse rates, was maintained in 77.8% of the respondents by 48 months (a median follow-up term). At this time, the antigen specific proliferative response was maintained in 66.7% of patients. The data obtained suggest that the dendritic-cell vaccines may be a promising approach to the treatment of recurrent labial and genital herpes.
format	article
author	O. Yu. Leplina N. M. Starostina D. D. Blinova O. I. Zheltova E. A. Oleinik T. V. Tyrinova A. A. Ostanin E. R. Chernykh
author_facet	O. Yu. Leplina N. M. Starostina D. D. Blinova O. I. Zheltova E. A. Oleinik T. V. Tyrinova A. A. Ostanin E. R. Chernykh
author_sort	O. Yu. Leplina
title	RESULTS OF A PILOT CLINICAL TRIAL OF DENDRITICCELL BASED VACCINES FOR TREATMENT OF RECURRENT HERPESVIRUS INFECTION
title_short	RESULTS OF A PILOT CLINICAL TRIAL OF DENDRITICCELL BASED VACCINES FOR TREATMENT OF RECURRENT HERPESVIRUS INFECTION
title_full	RESULTS OF A PILOT CLINICAL TRIAL OF DENDRITICCELL BASED VACCINES FOR TREATMENT OF RECURRENT HERPESVIRUS INFECTION
title_fullStr	RESULTS OF A PILOT CLINICAL TRIAL OF DENDRITICCELL BASED VACCINES FOR TREATMENT OF RECURRENT HERPESVIRUS INFECTION
title_full_unstemmed	RESULTS OF A PILOT CLINICAL TRIAL OF DENDRITICCELL BASED VACCINES FOR TREATMENT OF RECURRENT HERPESVIRUS INFECTION
title_sort	results of a pilot clinical trial of dendriticcell based vaccines for treatment of recurrent herpesvirus infection
publisher	SPb RAACI
publishDate	2016
url	https://doaj.org/article/d12c8a468ba3469c88b1c2fa7c457f10
work_keys_str_mv	AT oyuleplina resultsofapilotclinicaltrialofdendriticcellbasedvaccinesfortreatmentofrecurrentherpesvirusinfection AT nmstarostina resultsofapilotclinicaltrialofdendriticcellbasedvaccinesfortreatmentofrecurrentherpesvirusinfection AT ddblinova resultsofapilotclinicaltrialofdendriticcellbasedvaccinesfortreatmentofrecurrentherpesvirusinfection AT oizheltova resultsofapilotclinicaltrialofdendriticcellbasedvaccinesfortreatmentofrecurrentherpesvirusinfection AT eaoleinik resultsofapilotclinicaltrialofdendriticcellbasedvaccinesfortreatmentofrecurrentherpesvirusinfection AT tvtyrinova resultsofapilotclinicaltrialofdendriticcellbasedvaccinesfortreatmentofrecurrentherpesvirusinfection AT aaostanin resultsofapilotclinicaltrialofdendriticcellbasedvaccinesfortreatmentofrecurrentherpesvirusinfection AT erchernykh resultsofapilotclinicaltrialofdendriticcellbasedvaccinesfortreatmentofrecurrentherpesvirusinfection
_version_	1718422449001857024

RESULTS OF A PILOT CLINICAL TRIAL OF DENDRITICCELL BASED VACCINES FOR TREATMENT OF RECURRENT HERPESVIRUS INFECTION

Ejemplares similares